Comprehensive Evaluation of the m⁶A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma.

ABSTRACT:

Background

Clear cell renal cell carcinoma (ccRCC) is known for its high drug resistance. The tumor-immune crosstalk mediated by the epigenetic regulation of N6-methyladenosine (m⁶A) modification has been demonstrated in recent studies. Therefore, m⁶A modification-mediated immune cell infiltration characteristics may be helpful to guide immunotherapy for ccRCC.

Methods

This study comprehensively analyzed m⁶A modifications using the clinical parameters, single-cell RNA sequencing data, and bulk RNA sequencing data from the TCGA-ccRC cohort and 13 external validation cohorts. A series of bioinformatic approaches were applied to construct an m⁶A regulator prognostic risk score (MRPRS) to predict survival and immunotherapy response in

SUBMITTER: Yu M 

PROVIDER: S-EPMC9248360 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature